T
Takeshi Fujita
Researcher at Takeda Pharmaceutical Company
Publications - 51
Citations - 3321
Takeshi Fujita is an academic researcher from Takeda Pharmaceutical Company. The author has contributed to research in topics: Alkyl & Derivative (chemistry). The author has an hindex of 18, co-authored 51 publications receiving 3296 citations.
Papers
More filters
Journal ArticleDOI
Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth.
Donald E. Ingber,Takeshi Fujita,Shoji Kishimoto,Katsuichi Sudo,Tsuneo Kanamaru,Harold Brem,Judah Folkman +6 more
TL;DR: Synthesis of fumagillin analogues yielded potent angiogenesis inhibitors ('angioinhibins') which suppress the growth of a wide variety of tumours with relatively few side-effects.
Journal ArticleDOI
Potent anti-angiogenic action of AGM-1470 : comparison to the fumagillin parent
Masami Kusaka,Katsuichi Sudo,Takeshi Fujita,Shogo Marui,Fumio Itoh,Donald E. Ingber,Judah Folkman +6 more
TL;DR: The anti-angiogenic activity of AGM-1470, a new synthetic analog of fumagillin isolated from Aspergillus fumigatus, was extensively examined both in vitro and in vivo using four different types of assay and compared to that of the fumgillin parent.
Journal ArticleDOI
Reduction of Insulin Resistance in Obese and/or Diabetic Animals by 5-[4-(1-Methylcyclohexylmethoxy)benzyl]-thiazolidine-2,4-dione (ADD-3878, U-63,287, Ciglitazone), a New Antidiabetic Agent
Takeshi Fujita,Yasuo Sugiyama,Shigehisa Taketomi,Takashi Sohda,Yutaka Kawamatsu,Hisashi Iwatsuka,Ziro Suzuoki +6 more
TL;DR: Results show that ADD-3878 is effective on abnormal glucose and lipid metabolism associated with insulin resistance or obesity through reduction of peripheral insulin resistance and is expected to be useful in the treatment of hyperglycemie, hyperinsulinemia, and hyperlipemia in obese type II diabetes and Obesity.
Patent
Thiazolidinedione derivatives, useful as antidiabetic agents
Kanji Meguro,Takeshi Fujita +1 more
TL;DR: Thiazolidinedione derivatives of the formula: ##STR1## and pharmacologically acceptable salts thereof are novel compounds, which exhibit in mammals blood sugar and lipid-lowering activity, and are of value as a therapeutic agent for treatment of diabetes and hyperlipemia.
Journal Article
Inhibition of Tumor Growth and Metastasis of Rodent Tumors by the Angiogenesis Inhibitor O-(Chloroacetyl-carbamoyl)fumagillol (TNP-470; AGM-1470)
Masuo Yamaoka,Toshihiro Yamamoto,Tsuneo Masaki,Shuichi Ikeyama,Katsuichi Sudo,Takeshi Fujita +5 more
TL;DR: The results show that the angiogenesis inhibitor TNP-470 has strong inhibitory activities against in vivo growth and metastasis of a wide variety of tumors.